Denali Therapeutics Inc. DNLI
Set alert
18.94 USD -0.38 -1.97%
At close · Oct 30
19.00 +0.06 +0.32%
After hours · Oct 30, 4:59 PM ET
18.64 Day range 19.63
14.41 52-week range 27.21
- YTD
- +14.72%
- 1 year
- +15.63%
- Open
- 19.25
- Prev close
- 19.32
- Mkt cap
- 3.03B
- Vol
- 1.31M
- Avg vol
- 1.57M
- EPS
- -2.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.64
- High
- 19.63
- Forward P/E
- -7.84
- Beta
- 1.02
- Short ratio
- 7.76
- Inst. own
- 101.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 20.76
- 200-d avg
- 21.23
- 1y target
- 35.50
6M chart
Events in this range
- May 7, 2026Earnings: -0.69; estimate -0.73; surprise 5.48%
- May 14, 2026Rating: Morgan Stanley · Overweight → Overweight
- May 26, 2026Rating: Morgan Stanley · Overweight → Overweight
- Jul 16, 2026Rating: Deutsche Bank · Buy → Buy
- Jul 23, 2026Rating: Morgan Stanley · Overweight → Overweight
- Aug 6, 2026Earnings: -0.68; estimate -0.51305; surprise -32.54%
- Aug 7, 2026Rating: UBS · Buy → Buy
- Aug 25, 2026Rating: B. Riley Securities · Buy → Buy
Signals (35)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| RSI: Oversold | Sep 15, 2026 | 1 month ago |
| RSI: Oversold | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
Key statistics
- Market cap
- 3.03B
- Enterprise value
- 2.42B
- Trailing P/E
- 0.00
- Forward P/E
- -7.84
- PEG ratio
- 0.00
- Price / sales
- 840.04
- Price / book
- 3.62
- EPS (TTM)
- -2.84
- Beta
- 1.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.60M
- Revenue growth
- 0.00%
- Free cash flow
- -268.53M
- Total cash
- 710.47M
- Total debt
- 37.69M
- Return on equity
- -54.93%
- Shares outstanding
- 159.85M
- Short % of float
- 10.21%
- 50-day average
- 20.76
- 200-day average
- 21.23
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.50 +87.4% upside
Now 18.94
- Target (low)
- 23.00
- Target (mean)
- 35.50
- Target (high)
- 42.00
Ratings (0m) 20 19 buy · 1 hold · 0 sell
- Strong buy2
- Buy17
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.36666.
Financials — quick view
DNLI Revenue — quarterly 3.60M
DNLI Net income — quarterly -127.55M
DNLI EPS — quarterly -0.68
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.3222 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.51305 | -0.68 | -0.17 | -32.54% |
| May 7, 2026 | Mar 31, 2026 | -0.73 | -0.69 | +0.04 | +5.48% |
| Feb 26, 2026 | Dec 31, 2025 | -0.75 | -0.73 | +0.02 | +2.67% |
| Nov 6, 2025 | Sep 30, 2025 | -0.76 | -0.74 | +0.02 | +2.63% |
| Aug 11, 2025 | Jun 30, 2025 | -0.74 | -0.72 | +0.02 | +2.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 25, 2026 | B. Riley Securities | main | Buy | Buy |
| Aug 7, 2026 | UBS | main | Buy | Buy |
| Jul 23, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jul 16, 2026 | Deutsche Bank | main | Buy | Buy |
| May 26, 2026 | Morgan Stanley | main | Overweight | Overweight |
| May 14, 2026 | Morgan Stanley | main | Overweight | Overweight |
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- denalitherapeutics.com
News
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Denali Therapeutics Q2 2026 Earnings Call Transcript
- B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35
- UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34
- Denali Therapeutics Q2 EPS $(0.68) Misses $(0.65) Estimate, Sales $3.604M Miss $14.613M Estimate
- Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36
- Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35
- JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target
- Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195M
- Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35
Your note
Sign in to keep a note on DNLI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 2, 2026 | 0 |
| CHIN PETER SCOTT | Officer | Sale | Sep 3, 2026 | 204,538 |
| FLATLEY JAY T | Director | Stock Award(Grant) | Jun 2, 2026 | 358,941 |
| HO CAROLE | Officer | Sale | Aug 12, 2025 | 424,804 |
| KROGNES STEVE E | Director | Stock Award(Grant) | Jun 2, 2026 | 819,999 |
| SATO VICKI LEE | Director | Sale | Jan 1, 2025 | 107,976 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.12% | 16,178,963 | 306.43M | Jun 29, 2026 |
| Blackrock Inc. | 8.77% | 14,026,413 | 265.66M | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 7.48% | 11,960,230 | 226.53M | Jun 29, 2026 |
| State Street Corporation | 4.41% | 7,049,304 | 133.51M | Jun 29, 2026 |
| Temasek Holdings (Private) Ltd | 4.39% | 7,012,974 | 132.83M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.05% | 6,477,057 | 122.68M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 3.11% | 4,966,700 | 94.07M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.68% | 4,288,391 | 81.22M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.39% | 3,813,515 | 72.23M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.94% | 3,097,183 | 58.66M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.91% | 3,055,331 | 57.87M | Sep 29, 2026 |
| VANGUARD WORLD FUND-Vanguard U.S. Growth Fund | 1.90% | 3,037,857 | 57.54M | May 30, 2026 |